While many laboratories have adopted this technique for studying glioblastoma in vivo, two recent examples include injecting cells derived from isocitrate dehydrogenase 1 (IDH1)-mutant tumors into SCID (Severe Combined Immunodeficiency) mice to study vulnerability of this tumor genotype to 2-hydroxyglutarate depletion [9], and injecting cells from recurrent glioblastoma into NOD-SCID (Non-Obese Diabetic SCID) and NOG (NOD/Shi-scid/IL-2Rγnull) mice then treating them with a STAT3 (Signal Transducer and Activator of Transcription 3) inhibitor [10]. This evidence concerns the gene STAT3 and neoplasm.